» Articles » PMID: 25540591

Drug-induced Impairment of Renal Function

Overview
Publisher Dove Medical Press
Specialty Nephrology
Date 2014 Dec 26
PMID 25540591
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Pharmaceutical agents provide diagnostic and therapeutic utility that are central to patient care. However, all agents also carry adverse drug effect profiles. While most of these are clinically insignificant, some drugs may cause unacceptable toxicity that impacts negatively on patient morbidity and mortality. Recognizing adverse effects is important for administering appropriate drug doses, instituting preventive strategies, and withdrawing the offending agent due to toxicity. In the present article, we will review those drugs that are associated with impaired renal function. By focusing on pharmaceutical agents that are currently in clinical practice, we will provide an overview of nephrotoxic drugs that a treating physician is most likely to encounter. In doing so, we will summarize risk factors for nephrotoxicity, describe clinical manifestations, and address preventive and treatment strategies.

Citing Articles

Improving patient safety and access to healthcare: The role of pharmacist-managed clinics in optimizing therapeutic outcomes.

Thorakkattil S, Parakkal S, Mohammed Salim K, Arain S, Krishnan G, Madathil H Explor Res Clin Soc Pharm. 2024; 16:100527.

PMID: 39469652 PMC: 11513600. DOI: 10.1016/j.rcsop.2024.100527.


Exploring the Role of Phenolic Compounds in Chronic Kidney Disease: A Systematic Review.

Baptista F, Paie-Ribeiro J, Almeida M, Barros A Molecules. 2024; 29(11).

PMID: 38893451 PMC: 11173950. DOI: 10.3390/molecules29112576.


Evaluating the Safety of Herbal Medicine on Renal Function: A Comprehensive Analysis from Six Randomized Controlled Trials Conducted with Four Formulations from Traditional Korean Medicine.

Joung J, Son C Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794115 PMC: 11124499. DOI: 10.3390/ph17050544.


Elucidating Gender-Specific Distribution of Imipramine, Chloroquine, and Their Metabolites in Mice Kidney Tissues through AP-MALDI-MSI.

Islam M, Rahman M, Islam A, Afroz M, Mamun M, Rahman M Int J Mol Sci. 2024; 25(9).

PMID: 38732055 PMC: 11084644. DOI: 10.3390/ijms25094840.


Navigating Multiple Challenges: Malnutrition and Nephrotoxic Drug Effects in a Non-verbal Child With Autism Spectrum Disorder Requiring Dialysis.

Matsuura Y, Fune J, Ngai L Cureus. 2024; 16(3):e56951.

PMID: 38665731 PMC: 11044742. DOI: 10.7759/cureus.56951.


References
1.
Graham D, Staffa J, Shatin D, Andrade S, Schech S, La Grenade L . Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004; 292(21):2585-90. DOI: 10.1001/jama.292.21.2585. View

2.
Thorsteinsson S, Bergan T, Oddsdottir S, Rohwedder R, Holm R . Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy. 1986; 32(5):408-17. DOI: 10.1159/000238444. View

3.
Naesens M, Kuypers D, Sarwal M . Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009; 4(2):481-508. DOI: 10.2215/CJN.04800908. View

4.
Marples D, Christensen S, Christensen E, Ottosen P, Nielsen S . Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest. 1995; 95(4):1838-45. PMC: 295720. DOI: 10.1172/JCI117863. View

5.
Campbell W, Gomez-Sanchez C, Adams B, Schmitz J, Itskovitz H . Attenuation of angiotensin II- and III-induced aldosterone release by prostaglandin synthesis inhibitors. J Clin Invest. 1979; 64(6):1552-7. PMC: 371307. DOI: 10.1172/JCI109615. View